These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29379470)

  • 1. Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase.
    Hubbard SR
    Front Endocrinol (Lausanne); 2017; 8():361. PubMed ID: 29379470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
    Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
    J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.
    Staerk J; Kallin A; Demoulin JB; Vainchenker W; Constantinescu SN
    J Biol Chem; 2005 Dec; 280(51):41893-9. PubMed ID: 16239216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.
    Constantinescu SN; Leroy E; Gryshkova V; Pecquet C; Dusa A
    Biochem Soc Trans; 2013 Aug; 41(4):1048-54. PubMed ID: 23863177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
    Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
    Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Janus kinases (Jaks).
    Yamaoka K; Saharinen P; Pesu M; Holt VE; Silvennoinen O; O'Shea JJ
    Genome Biol; 2004; 5(12):253. PubMed ID: 15575979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
    Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
    J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders.
    Puleo DE; Kucera K; Hammarén HM; Ungureanu D; Newton AS; Silvennoinen O; Jorgensen WL; Schlessinger J
    ACS Med Chem Lett; 2017 Jun; 8(6):618-621. PubMed ID: 28626521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective.
    Staerk J; Constantinescu SN
    JAKSTAT; 2012 Jul; 1(3):184-90. PubMed ID: 24058768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling.
    Raivola J; Haikarainen T; Silvennoinen O
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31892268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling.
    Leroy E; Balligand T; Pecquet C; Mouton C; Colau D; Shiau AK; Dusa A; Constantinescu SN
    J Allergy Clin Immunol; 2019 Jul; 144(1):224-235. PubMed ID: 30707971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the structure and function of the pseudokinase domain in JAK2.
    Silvennoinen O; Ungureanu D; Niranjan Y; Hammaren H; Bandaranayake R; Hubbard SR
    Biochem Soc Trans; 2013 Aug; 41(4):1002-7. PubMed ID: 23863170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzymatic Characterization of Wild-Type and Mutant Janus Kinase 1.
    Liau NPD; Laktyushin A; Morris R; Sandow JJ; Nicola NA; Kershaw NJ; Babon JJ
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31683831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
    Vainchenker W; Dusa A; Constantinescu SN
    Semin Cell Dev Biol; 2008 Aug; 19(4):385-93. PubMed ID: 18682296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.
    Lupardus PJ; Ultsch M; Wallweber H; Bir Kohli P; Johnson AR; Eigenbrot C
    Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8025-30. PubMed ID: 24843152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the janus kinase family increases extracellular signal-regulated kinase 1/2 phosphorylation and causes endoreduplication.
    Reiterer G; Yen A
    Cancer Res; 2006 Sep; 66(18):9083-9. PubMed ID: 16982750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK/STAT signaling in hematological malignancies.
    Vainchenker W; Constantinescu SN
    Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
    Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
    Front Immunol; 2022; 13():884399. PubMed ID: 35693820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways.
    Neilson LM; Zhu J; Xie J; Malabarba MG; Sakamoto K; Wagner KU; Kirken RA; Rui H
    Mol Endocrinol; 2007 Sep; 21(9):2218-32. PubMed ID: 17550976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.